Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (221-230 of 271) with videos related to

Pageof 28
Sort By:
The Journal of Infectious Diseases|April 24, 2024
A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV PreventionSharon A Riddler, Clifton W Kelly, Craig J Hoesley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 18, 2014
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx StudyAlbert Liu, David V Glidden, Peter L Anderson, et al.
BMJ Open|July 2, 2021
The Magnetic Couples Study: protocol for a mixed methods prospective cohort study of HIV-serodifferent heterosexual couples' perspectives and use of pre-exposure prophylaxis (PrEP)James M McMahon, Janie Simmons, Jessica E Haberer, et al.
Journal of the International AIDS Society|April 19, 2017
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration projectBrenda Hoagland, Ronaldo I Moreira, Raquel B De Boni, et al.
The Lancet. HIV|February 13, 2026
Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trialFelix G Mhlanga, Daniel W Szydlo, Ashley J Mayo, et al.
The Lancet. HIV|October 31, 2025
Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b studyLee Fairlie, Daniel W Szydlo, Ashley Mayo, et al.
The Lancet. HIV|February 23, 2018
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration studyBeatriz Grinsztejn, Brenda Hoagland, Ronaldo I Moreira, et al.
Journal of the International AIDS Society|December 15, 2021
Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort studyJose R Castillo-Mancilla, Johnathan A Edwards, Jaysingh Brijkumar, et al.
Science Translational Medicine|September 14, 2012
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with menPeter L Anderson, David V Glidden, Albert Liu, et al.
AIDS (London, England)|August 4, 2025
Tenofovir diphosphate concentrations in dried blood spots predict future HIV suppression but not virologic failure in adolescents with HIVSampson Antwi, Hongmei Yang, Anthony Enimil, et al.
Pageof 28

Showing results (221-230 of 271) with videos related to

Sort By:
Pageof 28
The Journal of Infectious Diseases|April 24, 2024
A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV PreventionSharon A Riddler, Clifton W Kelly, Craig J Hoesley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 18, 2014
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx StudyAlbert Liu, David V Glidden, Peter L Anderson, et al.
BMJ Open|July 2, 2021
The Magnetic Couples Study: protocol for a mixed methods prospective cohort study of HIV-serodifferent heterosexual couples' perspectives and use of pre-exposure prophylaxis (PrEP)James M McMahon, Janie Simmons, Jessica E Haberer, et al.
Journal of the International AIDS Society|April 19, 2017
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration projectBrenda Hoagland, Ronaldo I Moreira, Raquel B De Boni, et al.
The Lancet. HIV|February 13, 2026
Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trialFelix G Mhlanga, Daniel W Szydlo, Ashley J Mayo, et al.
The Lancet. HIV|October 31, 2025
Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b studyLee Fairlie, Daniel W Szydlo, Ashley Mayo, et al.
The Lancet. HIV|February 23, 2018
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration studyBeatriz Grinsztejn, Brenda Hoagland, Ronaldo I Moreira, et al.
Journal of the International AIDS Society|December 15, 2021
Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort studyJose R Castillo-Mancilla, Johnathan A Edwards, Jaysingh Brijkumar, et al.
Science Translational Medicine|September 14, 2012
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with menPeter L Anderson, David V Glidden, Albert Liu, et al.
AIDS (London, England)|August 4, 2025
Tenofovir diphosphate concentrations in dried blood spots predict future HIV suppression but not virologic failure in adolescents with HIVSampson Antwi, Hongmei Yang, Anthony Enimil, et al.
Pageof 28